News & Events

Feb 26, 2013 BV 4 Portfolio Company Chiasma and Roche Announce Collaboration to Develop and Commercialize Chiasma�s Octreolin� for Acromegaly and Neuroendocrine Tumors | Download PDF version
Nov 28, 2012 BV 5 Portfolio Company Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor | Download PDF version
Nov 07, 2012 BV 4 and BV 5 Portfolio Company Astute Medical, Inc. named by WSJ as Top 10 Venture-Backed Health-Care Company
Nov 07, 2012 BV 3 Portfolio Company Portola Pharmaceuticals named as Top Ten Venture-Backed Health-Care Company
Oct 01, 2012 BV 4 Portfolio Company Epizyme Publishes Landmark Data on Personalized Therapeutics for Lymphomas | Download PDF version
Sep 28, 2012 BV 5 Portfolio Company Aratana Therapeutics Appoints Louise Mawhinney Chief Financial Officer | Download PDF version
Sep 18, 2012 BV 5 Portfolio Company Selexys Pharmaceuticals Completes $23M Equity Financing | Download PDF version
Sep 17, 2012 BV 5 Portfolio Company Vascular Pharmaceuticals, Inc. Completes $16 Million Equity Financing, Signs Agreement with Janssen Biotech, Inc.
Sep 12, 2012 BV 5 Portfolio Company Aratana appoints Co-Founder and Director Steven St. Peter, M.D., as President and Chief Executive Officer | Download PDF version
Jul 23, 2012 BV 4 Portfolio Company Chiasma Closes $38.5 Million Equity Financing | Download PDF version
Jul 10, 2012 Dr. Mirko Scherer and Sebastian Meier-Ewert, Ph.D. join MPM Senior Investment Team | Download PDF version
Jul 02, 2012 BV 4 Portfolio Company EKR Therapeutics Acquired by Cornerstone Therapeutics
Jun 25, 2012 BV 4 & BV 5 Portfolio Company Astute Medical Completes $40.4 Million Series C Financing | Download PDF version
Jun 14, 2012 BV 5 Portfolio Company Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
May 22, 2012 BV 5 Portfolio Company Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
May 07, 2012 BV 4 Portfolio Company Celladon Corporation Completes Second Close of Recent Venture Financing
Apr 26, 2012 BV 4 Portfolio Company Epizyme Forms Strategic Partnership with Celgene to Develop Personalized Therapeutics for Genetically-Defined Cancers | Download PDF version
Apr 23, 2012 BV 4 Portfolio Company Syndax Pharmaceuticals Appoints Arlene Morris as CEO | Download PDF version
Apr 12, 2012 BV 4 Portfolio Company Pacira Pharmaceuticals, Inc. Prices Public Offering of Common Stock
Mar 30, 2012 Former Portfolio Company Affymax and Takeda Announce FDA Approval of OMONTYS | Download PDF version
Mar 27, 2012 BV 4 Portfolio Company Celladon Corporation Completes $43 Million Financing to Advance MYDICAR� for the Treatment of Heart Failure
Dec 20, 2011 BV 4 Porfolio Company ForteBio, Inc. Enters Agreement to be Acquired by Pall Corp.
Dec 07, 2011 BV 5 Portfolio Company Aratana Therapeutics Completes $15 Million Series B Financing | Download PDF version
Nov 21, 2011 BV 3 Portfolio Company Portola Pharmaceuticals Announces Completion of $89 Million Financing | Download PDF version
Oct 31, 2011 BV 4 Portfolio Company Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL(TM) For Postsurgical Pain Management
Oct 27, 2011 BV 3 Portfolio Company Portola Pharmaceuticals and Biogen Idec Announce Global Collaboration | Download PDF version
Oct 05, 2011 BV 4 Portfolio Company Valeritas Announces $150 Million Financing
Jul 25, 2011 BV 4 Portfolio Company Nevro Corp Closes $58 Million in New Financing
Jul 20, 2011 BV 4 Portfolio Company Epizyme and Collaborators Publish Paper in CANCER CELL | Download PDF version
May 24, 2011 BV 3 Portfolio Company Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study | Download PDF version
May 24, 2011 BV 3 Portfolio Company Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis | Download PDF version
Mar 30, 2011 BV 4 Portfolio Company Nevro Appoints Michael DeMane President and Chief Executive Officer | Download PDF version
Mar 10, 2011 BV 4 Portfolio Company Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme | Download PDF version
Feb 01, 2011 BV 4 Portfolio Company iPierian and Kyoto University, IPS Academia Japan Announce Global Licensing and Patent Assignment Agreement
Jan 10, 2011 BV 4 Portfolio Company Epizyme Announces Strategic Alliance to Develop Epigenetic Therapeutics | Download PDF version
Jan 07, 2011 BV 4 Portfolio Company 23andMe Announces Additional Investment in Series C Financing
Dec 08, 2010 BV 1 and BV 4 Portfolio Company Valeritas Receives FDA 510(k) Clearance for the V-Go� Disposable Insulin Delivery Device
Dec 01, 2010 BV5 Portfolio Company Verastem Highlighted in December 1 Boston Globe article "Focus Turns to Cancer Stem Cells"
Nov 19, 2010 BV 5 Portfolio Company Verastem Secures $16 Million in Series A Financing for Novel Cancer Stem Cell Drugs
Sep 21, 2010 BV 5 Portfolio Company Rhythm Closes $40 Million Series A Financing | Download PDF version
Sep 17, 2010 BV 4 Portfolio Company iPierian named by FierceBiotech as One of the "Fierce 15" Biotech Companies of 2010
Sep 08, 2010 BV 4 Portfolio Company iPierian Announces Second Close of $28 million Series B Financing
Jul 21, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals: Lilly Announces Completion of Acquisition | Download PDF version
Jul 08, 2010 BV 4 Portfolio Company iPierian Closes $22 Million Series B Financing Led By Google Ventures | Download PDF version
Jul 06, 2010 BV 2 Portfolio Company SenoRx Completes Sale to C. R. Bard | Download PDF version
Jul 02, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals to be Acquired by Lilly | Download PDF version
Jun 28, 2010 BV 4 Portfolio Company Chiasma Receives Orphan Drug Designation From The FDA | Download PDF version
Jun 28, 2010 BV 2 Portfolio Company CGI Pharmaceuticals to be Acquired by Gilead for Up to $120 Million | Download PDF version
Jun 21, 2010 BV 5 Portfolio Company Rhythm announces RM-493 Reverses Obesity and Insulin Resistance in Obese Primates
Jun 14, 2010 BV 4 Portfolio Company Chiasma announces successful oral delivery of a peptide in a clinical trial and plans to initiate a pivotal trial by year end | Download PDF version
May 20, 2010 BV 5 Portfolio Company Neurotherapeutics Pharma Closes $43 Million Series B Financing and Adds Four New Investors | Download PDF version
May 05, 2010 BV 2 Portfolio Company SenoRx to be Acquired by C. R. Bard for Approximately $213 Million | Download PDF version
Apr 30, 2010 BV 4 Portfolio Company iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular
Apr 01, 2010 BV 3 & BV 4 Portfolio Company Xanodyne and Ferring Announce Co-Promote for Zipsor
Mar 29, 2010 BV 4 Portfolio Company Epizyme Expands Leadership Team, Appointing Robert Gould, Ph.D. as CEO and Jason Rhodes as EVP and CBO
Mar 15, 2010 BV 3 Portfolio Company Portola Pharmaceuticals and Merck Announce Results of Phase 2 Study of Betrixaban
Mar 15, 2010 BV 5 Portfolio Company Rhythm Announces $21 Million Series A | Download PDF version
Mar 02, 2010 BV 3 Portfolio Company CombinatoRx Achieves $40 Million Milestone | Download PDF version
Feb 25, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals Expands Leadership Team and Scientific Advisory Board (pdf) | Download PDF version
Jan 29, 2010 First iPierian (a BV4 Portfolio Company) Patent for Induced Pluripotent Stem Cell Technology Granted by the United Kingdom Intellectual Property Office | Download PDF version
Jan 28, 2010 MPM BV4 leads $35mm Series B financing for Alnara Pharmaceuticals
Jan 26, 2010 Paper entitled �Protein Methyltransferases as Target Class for Drug Discovery� by BV4 Portfolio Company Epizyme Scientists published in Nature Reviews Drug Discovery
Jan 22, 2010 BV3 Portfolio Company Somaxon Provides Update On New Drug Application For SILENOR� For The Treatment Of Insomnia
Jan 20, 2010 Gambro announces agreement to acquire CHF Solutions, Inc., a BV1 & BV3 Portfolio Company
Jan 19, 2010 BV4 Portfolio Company Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products | Download PDF version
Jan 06, 2010 BV3 Portfolio Company CombinatorRx Announces Senior Management Team Changes
Dec 22, 2009 BV3 Portfolio Company Neuromed and CombinatoRx Close Merger
Dec 22, 2009 BV4 Portfolio Company iPierian Highlighted In December 17, 2009 New York Times Article
Dec 04, 2009 Proteon Therapeutics Named 2010 Technology Pioneer by the World Economic Forum | Download PDF version
Dec 02, 2009 BV4 Portfolio Company Pacira Pharmaceuticals Announces Results of Another Positive Phase III Trial in Post Operative Pain
Nov 20, 2009 BV4 Portfolio Company TriVascular, Inc. Secures $30 Million in Equity Financing
Nov 20, 2009 BV2 Portfolio Company EKR Therapeutics Named Private Company of the Year By New Jersey Technology Council
Nov 20, 2009 ABC News Segment on BV4 Portfolio Company iPierian
Nov 12, 2009 BV4 Portfolio Company Peplin Acquired By LEO Pharma | Download PDF version
Nov 09, 2009 BV4 Portfolio Company NeoVista, Inc. Announces Initial VIDION� Shipments | Download PDF version
Nov 06, 2009 BV4 Portfolio Company NeoVista�, Inc. Completes Enrollment in Pivotal CABERNET� Study
Nov 05, 2009 BV2 Portfolio Company Biovitrum AB to Purchase Drug Company Swedish Orphan | Download PDF version
Nov 03, 2009 BV4 Portfolio Company EKR Therapeutics Receives Notice of Patent Allowance for Ready-to-Use Cardene� I.V. Bags
Nov 03, 2009 BV4 Portfolio Company Epizyme Appoints Hoyoung Huh, MD, Ph.D., Chairman of the Board of Directors
Oct 21, 2009 BV4 Portfolio Company iPierian To Collaborate with Johns Hopkins University on $3.7 Million NIH Grand Opportunities Grant
Oct 08, 2009 BV4 Portfolio Company Epizyme Closes $32 Million Series B Financing
Sep 17, 2009 BV4 Portfolio Company iPierian Featured In Forbes Magazine Article, October 5, 2009 Issue: "Growing Diseases In A Dish�
Sep 10, 2009 BV3 Portfolio Company Quatrx Announces Positive Results Of Second Pivotal Phase 3 Clinical Study | Download PDF version
Sep 07, 2009 BV2 Portfolio Company PrimeraDx closes $20m Series C
Sep 03, 2009 LEO Pharma to Acquire BV3 & BV4 Portfolio Company Peplin for US$287.5m | Download PDF version
Aug 24, 2009 BV2 & BV3 Portfolio Company EGS Announces Initiation of Clinical Study to Demonstrate Efficacy of StomaphyX for Revisional Weight Loss Surgery
Jul 09, 2009 Merck & Co., Inc. and BV3 Portfolio Company Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, | Download PDF version
Jul 08, 2009 iZumi Bio and Pierian Merge to form BV4 Portfolio Company iPierian to Advance Cellular Reprogramming | Download PDF version
Jul 08, 2009 CEO of BV2 Portfolio Company AVEO Pharmaceuticals discusses testing strategies
Jul 07, 2009 BV3 Portfolio Company Somaxon Pharma PIPEs $6 Million
Jul 02, 2009 Four MPM companies listed in the �Fierce 15� for 2009
Jul 02, 2009 BV3 Portfolio Company Neuromed and CombinatoRx Sign Merger Agreement | Download PDF version
Jun 25, 2009 Howard Weisman, Chairman & CEO of BV4 Portfolio Company EKR Therapeutics, Named Ernst & Young Entrepreneur Of The Year� 2009 Award Winner For The New Jersey Pharmaceutical Industry | Download PDF version
Jun 17, 2009 BV3 & BV4 Portfolio Company Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR� (diclofenac potassium) Liquid Filled Capsules
Jun 17, 2009 BV3 Portfolio Company Neuromed Announces Sale of U.S. Rights to Drug Candidate to Exgalgo� to Mallinckrodt | Download PDF version
Jun 11, 2009 Proteon Founders Named Entrepreneurs Of The Year� 2009 Award Winners in the Central Midwest Region | Download PDF version
Jun 05, 2009 BV3 & BV4 Portfolio Company Xanodyne Announces New President/CEO and Completes $38 million equity financing | Download PDF version
Jun 01, 2009 BV1 & BV4 Portfolio Company Valeritas Announces Appointment of New CEO
May 29, 2009 Proteon Therapeutics Completes Second Closing of Equity Financing | Download PDF version
May 26, 2009 BV2 Portfolio Company Elixir Pharmaceuticals Signs Option Agreement with a Major Pharmaceutical Company | Download PDF version